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Abstract
Background—The relationship between sildenafil dosing, exposure, and systemic hypotension 
in infants is incompletely understood.
Objectives—Characterize the relationship between predicted sildenafil exposure and 
hypotension in hospitalized infants.
Methods—We extracted sildenafil dosing and clinical characteristics from electronic health 
records of 348 neonatal intensive care units (1997–2013), and we predicted drug exposure using a 
population pharmacokinetic model.
Results—We identified 232 infants receiving sildenafil at a median dose of 3.2 mg/kg/day (2.0, 
6.0). The median steady-state area under the concentration time curve over 24 hours (AUC24,SS) 
and maximum concentration of sildenafil (CmaxSS,SIL) were 712 ng*hr/mL (401, 1561) and 129 
ng/mL (69, 293). Systemic hypotension occurred in 9% of the cohort. In multivariable analysis, 
neither dosing nor exposure were associated with systemic hypotension (odds ratio=0.96 [95% 
confidence interval: 0.81, 1.14] sildenafil dose; 0.87 [0.59, 1.28] AUC24,SS; 1.19 [0.78, 1.82] 
Cmax,SS,SIL).
Conclusions—We found no association between sildenafil dosing or exposure with systemic 
hypotension. Continued assessment of sildenafil’s safety profile in infants is warranted.
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INTRODUCTION
Sildenafil is a potent type-5 phosphodiesterase inhibitor increasingly used off label in 
infants.1,2 Despite this increasing use, sildenafil’s safety profile in infants remains poorly 
defined. Anecdotally reported adverse events associated with sildenafil therapy include 
bleeding, ocular anomalies, changes in cerebral blood flow, and systemic hypotension.3,4
Systemic hypotension is particularly significant given the hemodynamic instability 
frequently present in infants receiving sildenafil.5–7 Prior studies evaluating sildenafil’s 
safety in infants are contradictory.5,7–10 These findings may be due to differences in dosing 
and drug exposure, as evidenced by the wide range of observed plasma concentrations of 
sildenafil in prior pharmacokinetic studies.11,12 Because of this variability, a complete 
investigation of the cardiovascular safety profile of sildenafil in infants will require 
evaluation of drug dosing and exposure.
Safety studies in infants are challenging, and evaluation of drug exposure adds to the 
complexity.13 Novel strategies are urgently needed to overcome limitations of traditional 
studies, including large sample sizes and blood draws to measure drug concentrations.14 As 
a potential solution, we predicted individual sildenafil exposures using a published 
population pharmacokinetic model and combined them with electronic health record data 
from a large cohort of hospitalized infants. We hypothesized that increasing sildenafil 
exposures will be associated with clinically significant systemic hypotension.
MATERIALS AND METHODS
Data source and patient population
We used an electronic health record-derived database populated by admission notes, 
discharge summaries, and progress notes written by neonatologists caring for infants 
admitted to 1 of 348 Pediatrix Medical Group neonatal intensive care units in North America 
from 1997 to 2013. Clinical data routinely collected during hospitalization are captured in a 
data warehouse maintained by the Pediatrix Medical Group for quality-improvement and 
research purposes.15 We included all infants of 24–41 weeks gestational age at birth who 
received at least one day of enteral sildenafil during their hospitalization, to match the 
demographics of infants included in a published population pharmacokinetic model (Figure 
1).11 We excluded intravenous doses of sildenafil, and infants with incomplete dosing 
records or missing information on survival status at discharge. This study was approved by 
the Duke University Institutional Review Board without the need for written informed 
consent.
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Definitions
The unit of observation for analysis was a course of sildenafil therapy. A course was defined 
as consecutive days of therapy with sildenafil at the same dose, dosing interval, and route. 
Any change to dosing or interruption in dosing for one or more days constituted a new 
course. We extracted total daily sildenafil dose in mg/kg/day and dosing interval. We defined 
“small for gestational age” as previously described.16 We identified severity of illness 
surrogates including daily use of mechanical ventilation, any inotrope (amrinone, 
dobutamine, dopamine, epinephrine, milrinone, norepinephrine, or phenylephrine), any other 
pulmonary vasodilator (inhaled nitric oxide, bosentan, or epoprostenol), and the presence of 
a positive blood culture with organisms not typically considered contaminants. We defined 
exposure to cytochrome P450 3A4 (CYP3A4) inducers as concomitant exposure to either 
rifampin or bosentan. We defined exposure to CYP3A4 inhibitors as concomitant exposure 
to either fluconazole, ketoconazole, voriconazole, clarithromycin, or erythromycin.
The primary outcome was systemic hypotension diagnosed during a sildenafil treatment 
course. We defined systemic hypotension as either new exposure to a vasopressor 
(dobutamine, dopamine, epinephrine, norepinephrine, or phenylephrine) or discontinuation 
of an antihypertensive (angiotensin-converting enzyme inhibitor, beta-blocker, calcium 
channel blocker, tolazoline, phentolamine, nitroprusside, nitroglycerin, hydralazine, or 
clonidine). We performed a sensitivity analysis defining systemic hypotension as new 
exposure to vasopressor only.
Exposure predictions
To simulate sildenafil exposure, we used a published infant population pharmacokinetic 
model consisting of a one-compartment structural model for sildenafil and its primary active 
metabolite desmethylsildenafil with combined additive and proportional residual errors.11 
Using nonlinear mixed effects modeling methods, this model quantifies the different sources 
of variability in the dose-concentration relationship, including within- and between-subject 
variability and residual variability, and seeks to identify the measurable pathophysiologic 
factors responsible for the differences observed between subjects. When dose-concentration 
relationships vary between subjects, as is common in critically ill infants, the population 
pharmacokinetic model can predict concentrations of sildenafil based on dose received and 
specific clinical characteristics, rather than simply having to assume that concentrations 
achieved depend only on dose administered. The final model included weight (WT) as an 
allometrically scaled covariate for clearance (CL) and volume of distribution (V) for both 
parent and metabolite: sildenafil ; sildenafil V (L/70kg) = 
596 * (WT/70); desmethylsildenafil ; desmethylsildenafil 
V(L/70kg) = 245 * (WT/70). The first-order absorption rate constant was fixed at 2.4 hr−1. 
Interindividual variability was included on sildenafil clearance and V, and on 
desmethylsildenafil clearance, with separate residual variabilities for parent and metabolite. 
We used infant daily weight and dosing information from the electronic health record to 
simulate daily sildenafil and desmethylsildenafil exposure as maximum concentration at 
steady-state (CmaxSS,SIL and CmaxSS,DMS) and area under the concentration versus time 
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curve from 0 to 24 hours at steady-state using NONMEM version 7.3 (Icon Development 
Solutions, Ellicott City, MD) (Supplementary Table S1).
To represent total pharmacologic exposure of sildenafil, the area under the sildenafil 
concentration time curve from 0 to 24 hours at steady-state (AUC24,SS,SIL) was added to half 
the area under the desmethylsildenafil concentration versus time curve from 0 to 24 hours at 
steady-state (AUC24,SS,DMS) (AUC24,SS,SIL+DMS = AUC24,SS,SIL + 0.5 * AUC24,SS,DMS), as 
done in the original model publication.11 Due to an insufficient number of infants exposed to 
fluconazole, we did not include it as a covariate effect; instead, we included concomitant 
exposure to any CYP3A4 inducer or inhibitor in the multivariable regression.
Statistical analysis
We used summary statistics including medians (interquartile ranges) and counts 
(percentages) to describe continuous and categorical variables. We compared distribution of 
variables using Wilcoxon rank-sum, chi-square, and Fisher’s exact tests as appropriate. We 
used Spearman’s rank correlation to describe relationships between sildenafil dose and 
CmaxSS,SIL and AUC24,SS,SIL+DMS. We used multivariable logistic regression with random 
effects for neonatal intensive care unit to evaluate associations between systemic 
hypotension and sildenafil dosing, CmaxSS,SIL, and AUC24,SS,SIL+DMS, which were centered 
and scaled prior to inclusion in the regression, e.g., CmaxSS,SIL,center−scale = (CmaxSS,SIL − 
mean(Cmaxss,SIL)/standard deviation(CmaxSS,SIL). We fit separate models for total daily 
sildenafil dose, AUC24,SS,SIL+DMS, and CmaxSS,SIL (3 models total), all including the 
following as covariates: postnatal age in days, weight, gestational age, small for gestational 
age, mechanical ventilation, inotropes, other pulmonary vasodilators, and exposure to 
CYP3A4 inducers or inhibitors. Because an association between systemic hypotension and 
younger postnatal age became apparent in our analysis, and because younger infants treated 
with sildenafil may be more likely to suffer from persistent pulmonary hypertension of the 
newborn, we conducted a second sensitivity analysis limited to infants with this diagnosis. 
We reported adjusted odds ratios and 95% confidence intervals for systemic hypotension. 
We conducted statistical analyses using STATA SE 14.1 (College Station, TX), and 
considered P values <0.05 to be statistically significant.
RESULTS
We identified 232 infants exposed to 278 sildenafil courses for 2327 infant-days of therapy 
(Table 1). Median (interquartile range) gestational age and birth weight were 27 weeks (25, 
36) and 775 g (593, 2368). Median postnatal age and postmenstrual age on the first day of 
sildenafil exposure were 85 days (21, 126) and 41 weeks (38, 44). Only 20% of infants were 
<37 weeks postmenstrual age when starting sildenafil. Over half of infants (55%) were 
receiving mechanical ventilation, and 30% were exposed to another pulmonary vasodilator 
when starting sildenafil. The most commonly used pharmacologic pulmonary vasodilator 
other than sildenafil was inhaled nitric oxide administered to 30% of infants, while bosentan 
(<1%) and epoprosterenol (1%) were administered less frequently. The median daily 
fraction of inspired oxygen on the first day of sildenafil therapy was 50% (35%, 100%), and 
57% of infants were on >50% fraction of inspired oxygen. The median dose of sildenafil 
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was 1.0 mg/kg/dose (0.6, 1.7) or 3.2 mg/kg/day (2.0, 6.0). The most common dosing 
intervals were every 6 (55%) and every 8 hours (27%). Mean (5th, 95th percentile) treatment 
course duration was 8.5 days (1, 46). The most common diagnoses potentially associated 
with sildenafil were persistent pulmonary hypertension of the newborn in 195/232 (84%) 
infants and bronchopulmonary dysplasia in 179/232 (77%) infants. Other diagnoses 
potentially associated with sildenafil use included congenital diaphragmatic hernia (24/232, 
10%), pulmonary hypoplasia (20/232, 9%), and meconium aspiration syndrome (10/232, 
4%).
Systemic hypotension occurred in 10% (24/232) of infants and 9% (25/278) of therapy 
courses. Of the 24 infants with hypotension, 18 were started on an inotrope or had an 
increase in the number of inotropes, and 6 infants had their antihypertensive medications 
discontinued or the number of antihypertensive medications decreased. Of the 6 infants who 
had a decrease in antihypertensive medications, angiotensin-converting enzyme inhibitors 
were discontinued in 3 infants, calcium channel blockers in 1, beta-blockers in 1, and other 
antihypertensives in 1. Infants with systemic hypotension had a higher median birth weight 
(2108 g [870, 3071] versus 759 g [585, 2278], P=0.004), but the median weight on the day 
of first exposure did not differ (median 3094 g [2313, 3547] versus 3081 g [2418, 3768], 
P=0.79). There was no significant difference in the distribution of gestational age, but infants 
with systemic hypotension had lower median postmenstrual ages and postnatal ages on the 
day of first exposure (postmenstrual age: 39 weeks [37, 42] versus 41 weeks [38, 44], 
P=0.03; postnatal age: 17 days [3, 96] versus 89 days [25, 129]; P=0.002). Hypotension was 
diagnosed early in the course: median 0.5 days (0, 4) after the start of therapy. The median 
dose and total daily dose did not differ between infants with systemic hypotension versus 
those without (1.0 mg/kg [0.5, 1.4] versus 1.0 mg/kg [0.5, 1.5], P=0.42; and 3.0 mg/kg/day 
[1.8, 5.8] versus 3.3 mg/kg/day [2.0, 6.2], P=0.37). On the first day of therapy, 72% of 
infants diagnosed with systemic hypotension were receiving mechanical ventilation, and 
40% were exposed to another pulmonary vasodilator.
Median predicted AUC24,SS,SIL+DMS and CmaxSS,SIL were 712 ng*hr/mL (401, 1561) and 
129 ng/mL (69, 293). None of the predicted exposures differed between courses with or 
without systemic hypotension (Table 2). As anticipated, we observed a significant positive 
correlation between total daily dose and AUC24,SS,SIL+DMS (R=0.65, P<0.001) and 
CmaxSS,SIL (R=0.69, P<0.001). Concomitant administration of CYP3A4 inducers was rare 
(<1%), while CYP3A4 inhibitors were co-administered during 5% of treatment courses. The 
most commonly co-administered CYP3A4 inhibitor on days of sildenafil exposure was 
fluconazole (3%), followed by erythromycin (1%), while the most commonly co-
administered CYP3A4 inducer was rifampin (<1%).
In multivariable analysis, the total daily sildenafil dose was not associated with systemic 
hypotension (odds ratio=0.96 [95% confidence interval: 0.81, 1.14 per 1 standard deviation 
[SD] increase in total daily dose). We also found no association between predicted sildenafil 
exposures and systemic hypotension (Table 3). Results were similar in a sensitivity analysis 
defining systemic hypotension as a new exposure to inotropes only. Neither total daily dose 
(odds ratio=1.34, 95% confidence interval: 0.90, 1.99 per 1 SD increase in total daily dose), 
AUC24,SS,SIL+DMS (odds ratio=1.36, 95% confidence interval: 0.93, 1.97 per 1 SD increase 
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in AUC24,SS,SIL+DMS), or CmaxSS,SIL (odds ratio=1.34, 95% confidence interval: 0.85, 2.10 
per 1 SD increase in CmaxSS,SIL) were associated with increased odds of systemic 
hypotension. Results were also unchanged when all 3 regressions were repeated in infants 
with persistent pulmonary hypertension of the newborn and when stratifying the study 
population by gestational age into term (≥37 weeks gestational age) vs. preterm (<37 weeks 
gestational age) infants: odds ratio=0.36 (0.18, 2.20) per 1 SD increase in total daily dose, 
odds ratio=5.02 (0.59, 42.45) per 1 SD increase in AUC24,SS,SIL+DMS, odds ratio=7.12 
(0.18, 285.88) per 1 SD increase in CmaxSS,SIL for full-term infants, odds ratio= 1.01 (0.85, 
1.21) per 1 SD increase in total daily dose, odds ratio=1.22 (0.80, 1.85) per 1 SD increase in 
AUC24,SS,SIL+DMS, odds ratio=0.66 (0.27, 1.58) per 1 SD increase in CmaxSS,SIL for 
preterm infants.
DISCUSSION
In a large group of hospitalized infants, we found that neither dosing nor predicted sildenafil 
exposure were associated with systemic hypotension after adjusting for infant characteristics 
and severity of illness surrogates. While our study is retrospective, it is the largest evaluation 
of sildenafil safety in infants, and it is the first study to use predicted sildenafil exposure to 
characterize safety.17
Sildenafil induces vasodilation through inhibition of type-5 phosphodiesterase.18 Because 
type-5 phosphodiesterase is predominantly expressed in the lungs, sildenafil is considered a 
selective pulmonary vasodilator.19,20 Despite this perceived pulmonary selectivity, systemic 
hypotension can occur due to direct passage of sildenafil into the systemic circulation 
through intra- and extra-cardiac shunts, due to direct negative effects of sildenafil on the 
neonatal myocardium, or as a result of variable levels of type-5 phosphodiesterase 
expression in the lungs with potential for off-target effects.9,21 Treatment-related systemic 
hypotension was first reported in 5 of 36 (14%) infants >34 weeks gestational age exposed 
to escalating doses of sildenafil via intravenous infusion.7 These findings are comparable to 
the 10% prevalence of hypotension found in our cohort. Two other prospective and one 
retrospective study of infants receiving enteral sildenafil failed to find serious cardiovascular 
adverse events; however, they lacked the sample size necessary to identify rare adverse 
events and did not assess drug exposure.5,9,22
Systemic drug exposure mediates the relationship between dosing and its safety profile and 
may be variable in critically ill infants.23,24 Early clinical studies suggested that this is the 
case for sildenafil. In the first open-label trial of intravenous sildenafil in infants, blood 
concentrations varied both between and within dose levels.7 This variability in exposure was 
confirmed using population pharmacokinetic modeling. In a study of intravenous sildenafil 
in 36 term infants with persistent pulmonary hypertension of the newborn, sildenafil 
clearance increased from 0.84 L/h for a 1-day old infant to 2.58 L/h at 7 days of age.12 The 
authors concluded that sildenafil pharmacokinetics in infants were best characterized by a 
model that accounted for the relationship between clearance and postnatal age but noted that 
despite this age effect, interindividual variability in clearance remained high (>50%). Similar 
conclusions were drawn from a single-center pharmacokinetic study of 11 infants receiving 
enteral sildenafil.11 Blood concentrations and calculated AUC24,SS,SIL+DMS varied, and 
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interindividual variability in pharmacokinetic parameters predicted using a 1-compartment 
model were >80% for both clearance and V. More recently, 30 blood concentrations 
obtained from 6 infants 24 to 39 weeks gestational age receiving a median (range) dose of 
0.9 mg/kg (0.5–2.1) of sildenafil per standard of care in an opportunistic pharmacokinetic 
study ranged from 2.6 to 434 ng/mL.25 These findings support the notion of variability in 
sildenafil exposure owing to variable pharmacokinetics, and that assessments of the drug’s 
safety require evaluation of drug exposure.
Performing a large-scale sildenafil safety study with blood concentration measurements in 
infants would be challenging. Fortunately, published pharmacokinetic models allowed us to 
predict drug exposure using infant characteristics and dosing information collected in 
electronic health records. Our predicted exposures were within the range reported in one 
prior pharmacokinetic trial but lower than in the cohort of infants used to derive the 
pharmacokinetic model applied in our study.11,12 This difference may be due to the higher 
doses administered to the pharmacokinetic model development cohort (mean 1.9 mg/kg/
dose) compared to the electronic health record cohort (mean 1.2 mg/kg/dose) or the younger 
postnatal age at the time of sildenafil dosing (mean 34 hours in the model development 
cohort versus mean 3.5 days in the electronic health record).
Despite the range of predicted sildenafil exposures in our study, we did not identify a 
relationship with systemic hypotension. Concerns about an exposure-safety relationship of 
sildenafil stem primarily from the results of the STARTS-2 trial.26 This open-label extension 
to the pivotal STARTS-1 study found increased mortality after 2 years of high-dose 
sildenafil in children >20 kg.26–28 Mortality was lower in children receiving low or medium 
dosing. While exposure data were not available for the long-term extension study, predicted 
geometric mean AUC of parent drug in children treated with high-dose sildenafil in the 16-
week STARTS-1 study ranged from 941 ng*hr/mL to 2193.6 ng*hr/mL, higher than 
exposures in the medium- and low-dose groups (114.8 ng*hr/mL to 769.5 ng*hr/mL).29 
Interpreting these findings has proven to be challenging, and their significance for infants 
remains debated.30,31 Even if one assumes that the observed exposure-safety relationship is 
true in older children, physiologic and disease-specific differences may explain why this 
does apply to infants. Disease states treated in infants such as persistent pulmonary 
hypertension of the newborn and concomitant therapy with high fractions of inspired oxygen 
may increase pulmonary type-5 phosphodiesterase activity and/or expression, resulting in 
improved on-target effects.21 Children in the long-term STARTS-2 trial were receiving 
outpatient sildenafil therapy for a variety of forms of pulmonary hypertension, but not 
persistent pulmonary hypertension of the newborn, and they were not exposed to high 
fractions of inspired oxygen.27 Given these differences and the potential benefits of 
sildenafil in infants, careful population-specific safety assessments are needed.
The strengths of our study included its novel, cost-effective, efficient, and minimal-risk 
design. Nevertheless, it is not without limitations. The dosing and safety data are derived 
from electronic health records, which have not undergone the development and scrutiny of a 
prospective trial database. Clinically significant hypotension was defined based on 
pharmacologic interventions, as blood pressure measurements were not available. This 
methodology likely underestimates the true prevalence of hypotension, but may serve as an 
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acceptable surrogate of the clinically significant events. This is particularly true in the 
neonatal population, in which defining hypotension based on blood pressure measurements 
remains challenging. As a result, neonatal clinical trial experts of the NICHD-funded 
Pediatric Trials Network concluded that for the assessment of drug safety, hypotension 
should be defined based on the need for vasopressors and inotropes, as was done in our 
study.32 Because the reason for discontinuing drugs is not provided in the electronic health 
record data available, we further did not include discontinuation of sildenafil as a surrogate 
for hypotension but acknowledge that this may be a common first intervention for infants 
experiencing this complication. Overall, the limitations in hypotension definitions likely led 
us to underestimate the true prevalence of this complication in premature infants. In order to 
predict exposures, we used a previously published population pharmacokinetic model 
derived in neonates, but we acknowledge that this model has not been externally validated.11 
Unfortunately, this limitation is common in pediatric pharmacokinetic models owing to the 
significant challenges of conducting prospective validation trials in this population. We 
further had to limit our study population to match the characteristics of the population used 
to develop the model, and therefore excluded infants receiving intravenous sildenafil. The 
original model publication does not provide information about gestational age, limiting our 
ability to compare it to the gestational age distribution in our cohort. However, the mean 
postnatal age and weight of the infants included in the model development cohort were 33 
days and 3.6 kg, suggesting that they are predominantly premature. This is consistent with 
our study population.11 Details of administration, such as formulations, concomitant 
nutrition, or use of a nasogastric tube, were not available. Further, the mean treatment 
duration of our cohort was short, limiting our ability to report on the long-term safety. 
Lastly, while we were able to adjust for several characteristics in our regression analyses, 
other risk factors not available in the electronic health record may lead to residual bias.
In conclusion, this large, novel sildenafil exposure-safety study in hospitalized infants found 
that neither dosing nor predicted exposure were associated with systemic hypotension. 
Given the known dose-concentration variability observed in premature infants, the use of 
exposure predictions strengthens the lack of observed association between sildenafil use and 
hypotension in this population. Our findings are consistent with the majority of recently 
conducted, smaller, retrospective and prospective studies supporting the safety of sildenafil 
in hospitalized infants.
Supplementary Material
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Figure 1. 
Study flow chart. GA=gestational age; PNA=postnatal age.
Hornik et al. Page 11
Cardiol Young. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hornik et al. Page 12
Table 1
Demographics
Infants with Hypotension
Yes
N=24
No
N=208
Gestational age at birth, weeks
≤ 25 6 (25%) 79 (38%)
26–28 3 (13%) 46 (22%)
29–32 3 (13%) 22 (11%)
33–36 4 (17%) 12 (6%)
≥ 37 8 (33%) 49 (24%)
Birth weight, g
< 1000 8 (33%) 127 (61%)
1000–1499 3 (13%) 14 (8%)
1500–2499 2 (8%) 25 (12%)
2500–3499 8 (33%) 32 (15%)
≥ 3500 3 (13%) 10 (5%)
Small for gestational age 2 (8%) 70 (34%)
Male gender 13 (54%) 117 (56%)
Inborn status 15 (63%) 163 (78%)
C-section 15 (63%) 149 (73%)
5-minute APGAR
0–3 2 (9%) 17 (8%)
4–6 8 (36%) 50 (25%)
7–10 12 (55%) 135 (67%)
Age at first exposure, days
< 7 8 (33%) 11 (5%)
7–29 5 (21%) 45 (22%)
30–59 2 (8%) 28 (13%)
60–119 5 (21%) 58 (28%)
≥ 120 4 (17%) 66 (32%)
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Table 2
Median (interquartile range) total daily dose and daily simulated exposures
Courses With Hypotension P
Yes N=25 No N=253
Sildenafil dose (mg/kg/day) 3.0 (1.8, 5.8) 3.3 (2.0, 6.2) 0.37
AUC24,SS,SIL+DMS (ng*hr/mL)a 721 (400, 1614) 711 (401, 1540) 0.84
Cmax,SS,SIL (ng/mL) 101 (53, 373) 129 (69, 287) 0.88
Cmax,ss,SIL: maximal sildenafil steady state concentration.
aAUC24,ss, SIL+DMS: 24-hour area under the concentration-time curve at steady-state, accounting for the contribution of the active 
desmethylsildenafil metabolite by adding 50% of this metabolite’s AUC to the corresponding value for the parent drug (AUC24,ss, SIL+DMS = 
AUC24,ss,SIL + 0.5*AUC24,ss,DMS).
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Table 3
Adjusted odds of hypotension
Odds Ratiob (95% confidence interval)
Sildenafil dose (mg/kg/day) 0.96 (0.81, 1.14)
AUC24,SS,SIL+DMS (ng*hr/mL)a 0.87 (0.59, 1.28)
Cmax,SS,SIL (ng/mL) 1.19 (0.78, 1.82)
Cmax,ss,SIL: maximal sildenafil steady state concentration.
aAUC24,ss, SIL+DMS: 24-hour area under the concentration-time curve at steady-state, accounting for the contribution of the active 
desmethylsildenafil metabolite by adding 50% of this metabolite’s AUC to the corresponding value for the parent drug (AUC24,ss, SIL+DMS = 
AUC24,ss,SIL + 0.5*AUC24,ss,DMS).
b
adjusted for postnatal age, daily weight, gestational age, small for gestational age status, exposure to inotropes, other pulmonary vasodilators, 
mechanical ventilation, CYP3A4 inducers or inhibitors, and random effects for site.
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